NasdaqGM - Nasdaq Real Time Price USD

Ligand Pharmaceuticals Incorporated (LGND)

115.46

-3.18

(-2.68%)

As of 2:37:15 PM EST. Market Open.

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model that comes from our 11 experienced analysts’ expertise and due diligence. Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based

Zacks Small Cap Research 18 days ago

MTVA

LGNZZ

TELO
Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

Simply Wall St. last month

LGND
-2.68%
LGNDZ

LGNXZ
LGND: 2025 View Calls for 17% Topline Growth

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10 th , 2024 in Boston. The company provided its 2025 expectations calling for topline revenues of $180 to $200 million and core adjusted earnings per share (EPS) of $6.00 to $6.25. This represents an approximate 17% increase at the midpoint

Zacks Small Cap Research last month

LGNZZ
Ligand price target raised to $151 from $135 at Oppenheimer

Oppenheimer raised the firm’s price target on Ligand (LGND) to $151 from $135 and keeps an Outperform rating on the shares following the company’s investor day. Key takeaways, the firm says, include capital needs within biotech/biopharma remain massive; investments will continue to be selective, and lean on their expertise; Zelsuvmi opportunity remains underappreciated; further levers of potential value creation exist with an emphasis on Captisol sales growth; and Captisol/Nitricil platform valu

TipRanks last month

LGND
-2.68%
LGNDZ

LGNXZ
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

JUPITER, Fla., December 10, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and other members of the senior management team who will provide an in-depth review of the company’s growth strategy, portfolio, platform technologies, and long-term financial outlook.

Business Wire last month

LGND
-2.68%
LGNDZ

LGNXZ
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Shareholders were pleased with the recent earnings report from Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND...

Simply Wall St. 2 months ago

LGND
-2.68%
LGNDZ

LGNXZ
Ligand to Present at Stifel 2024 Healthcare Conference

JUPITER, Fla., November 14, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time.

Business Wire 2 months ago

LGND
-2.68%
LGNDZ

LGNXZ
LGND: 3Q Sales Surprise to the Upside

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported third quarter results on November 7th, 2024. Revenues of $51.8 million were well ahead of our estimates due to contributions from Verona's Ohtuvayre, Qarziba and growth in Filspari. Core adjusted earnings of $1.84 were also ahead of our estimates. Top and bottom-line beats

Zacks Small Cap Research 2 months ago

LGNZZ
Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Ligand Pharmaceuticals ( NASDAQ:LGND ) Third Quarter 2024 Results Key Financial Results Revenue: US$51.8m (up 58% from...

Simply Wall St. 2 months ago

LGND
-2.68%
LGNDZ

LGNXZ
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Ligand Pharmaceuticals fair value estimate is US$259 Ligand...

Simply Wall St. 2 months ago

LGND
-2.68%
LGNDZ

LGNXZ
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Ligand Pharmaceuticals Inc (LGND) reports a 58% revenue increase and raises 2024 guidance, showcasing strong business momentum and strategic positioning.

GuruFocus.com 2 months ago

LGNZZ
Ligand: Q3 Earnings Snapshot

LGND) on Thursday reported a loss of $7.2 million in its third quarter. On a per-share basis, the Jupiter, Florida-based company said it had a loss of 39 cents. The results fell short of Wall Street expectations.

Associated Press Finance 2 months ago

LGNZZ
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

JUPITER, Fla., November 07, 2024--Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Business Wire 2 months ago

LGND
-2.68%
LGNDZ

LGNXZ
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

JUPITER, Fla., November 01, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time.

Business Wire 2 months ago

LGND
-2.68%
LGNDZ

LGNXZ
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

JUPITER, Fla., October 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update.

Business Wire 3 months ago

LGND
-2.68%
LGNDZ

LGNXZ
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman SachsWAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approve

GlobeNewswire 3 months ago

LGND
-2.68%
LGNDZ

LGNXZ
Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

Despite a significant revenue surge, Ligand Pharmaceuticals Inc (LGND) faces leadership transitions and investment impairments.

GuruFocus.com 3 months ago

LGNZZ
LGND: Initiating Coverage – A Prince Among Royalty

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreciation and amortization (EBITDA) and earnings estimates. Ligand is a biopharmaceutical royalty aggregator

Zacks Small Cap Research 3 months ago

LGNZZ
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?

Ligand Pharmaceuticals (NASDAQ:LGND) has had a great run on the share market with its stock up by a significant 28...

Simply Wall St. 4 months ago

LGND
-2.68%
LGNDZ

LGNXZ
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

JUPITER, Fla., September 06, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of FILSPARI.

Business Wire 4 months ago

LGND
-2.68%
LGNDZ

LGNXZ

Performance Overview

Return	LGND	S&P 500
YTD	+9.17%	+2.42%
1-Year	+56.22%	+22.84%
3-Year	+58.53%	+36.50%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ligand Pharmaceuticals Incorporated (LGND)

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year

LGND: 2025 View Calls for 17% Topline Growth

Ligand price target raised to $151 from $135 at Oppenheimer

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Ligand to Present at Stifel 2024 Healthcare Conference

LGND: 3Q Sales Surprise to the Upside

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price

Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Ligand: Q3 Earnings Snapshot

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

LGND: Initiating Coverage – A Prince Among Royalty

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Performance Overview